HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review (Q38058271)

27 August 2017

0 references

HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review (English)

1 reference

27 August 2017

4

1 reference

27 August 2017

V L Yip

1

1 reference

27 August 2017

A G Marson

series ordinal

2

1 reference

27 August 2017

A L Jorgensen

series ordinal

3

1 reference

27 August 2017

A Alfirevic

series ordinal

5

1 reference

27 August 2017

language of work or name

English

0 references

publication date

7 November 2012

1 reference

Clinical Pharmacology & Therapeutics

27 August 2017

published in

1 reference

27 August 2017

volume

92

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

757-765

1 reference

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Severe adverse cutaneous reactions to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Human leukocyte antigens and drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

HLA-B locus in Caucasian patients with carbamazepine hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Phenotype standardization for immune-mediated drug-induced skin injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

HLA-B* 1502 screening: time to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Drug hypersensitivity: pharmacogenetics and clinical syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Methodological quality of pharmacogenetic studies: issues of concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

7 January 2021

HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

7 January 2021

A marker for Stevens-Johnson syndrome ...: ethnicity matters

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

7 January 2021

Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.189

7 January 2021

Identifiers

DOI

10.1038/CLPT.2012.189

1 reference

27 August 2017

1 reference